5 results about "Glucose utilization" patented technology

The present invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transporter (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds in the treatment of cardiovascular diseases, disorders of fatty acid metabolism and glucose utilization, gastrointestinal diseases and liver diseases.

The invention provides an engineering strain for synthesizing homoserine by using ethylene glycol and application of the engineering strain. The engineering strain comprises an expression plasmid vector or an expression plasmid vector combination, the vector or combination comprises a first group of polynucleotides and a second group of polynucleotides, and the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme promoting ethylene glycol utilization; the second set of polynucleotides comprising at least one polynucleotide encoding an L-homoserine synthesis pathway enzyme; and a backbone plasmid capable of autonomously replicating in a host cell. By introducing the first group of polynucleotides, not only is the glucose utilization rate of the engineering strain improved, but also the yield of the L-homoserine is improved; meanwhile, by overexpressing or strengthening a plurality of L-homoserine biosynthetic pathway related genes from different sources and knocking out or weakening L-homoserine degradation pathway related genes, efficient fermentation production of the L-homoserine is realized.

The invention provides an engineering strain for synthesizing L-methionine by using ethylene glycol and application of the engineering strain. The engineering strain comprises an expression plasmid vector or an expression plasmid vector combination, the vector or combination comprises a first group of polynucleotides and a second group of polynucleotides, and the first group of polynucleotides comprises at least one polynucleotide encoding an enzyme promoting ethylene glycol utilization; the second set of polynucleotides comprising at least one polynucleotide encoding an L-methionine synthesis pathway enzyme; and a backbone plasmid capable of autonomously replicating in a host cell. By introducing the ethylene glycol utilization gene, not only is the utilization rate of glucose improved, but also the yield of L-methionine is improved; meanwhile, by overexpressing or strengthening a plurality of L-methionine biosynthetic pathway related genes from different sources and knocking out or weakening L-methionine degradation pathway or transcription inhibition factor related genes, efficient fermentation production of L-methionine is realized.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.